The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study
Open accessAbstract
Summary Background Obesity is associated with an increased risk of developing clear cell renal cell carcinoma (ccRCC) but, paradoxically, with improved oncologic outcomes. As the biologic mechanisms underlying this association are poorly understood, our study aimed to identify transcriptomic differences in primary tumor or peritumoral adipose tissue between obese and normal weight patients. Methods After confirming the inverse association between body mass index (BMI ≥ 30 vs < 30 kg/m2) and mortality in three independent clinical cohorts including 453 metastatic ccRCC patients treated with first-line VEGF-directed therapy from the Phase III COMPARZ clinical trial, 152 predominately early stage ccRCC patients from the Cancer Genome Atlas (TCGA), and a Memorial Sloan Kettering (MSK) observational cohort of 203 metastatic ccRCC patients treated with targeted immunotherapy using the Kaplan–Meier method and analyzed by log-rank test, we evaluated and validated primary tumor transcriptomic differences. We also compared gene expression differences in peritumoral adipose tissue from a prospectively collected cohort of patients with non-metastatic ccRCC. Wilcoxon rank-sum test was used to analyze significant differences in gene expression between groups and false discovery correction was performed using the Benjamini-Hochberg procedure. Findings A lower mortality rate was observed in obese patients versus normal weight patients in the in the locally advanced The Cancer Genome Atlas cohort (median OS not-reached (NR), 95%CI 53.45-NR vs 25.30 mos, 95%CI 14.18–39.47, respectively; adjusted-Hazard Ratio (aHR) 0·41, 95%CI 0·22–0·75), and COMPARZ trial cohort of metastatic ccRCC treated with tyrosine kinase inhibitors (median OS 35.65, 95%CI 27.66-NR vs 19.06, 95%CI 15.31–27.80, respectively; aHR 0·68, 95%CI 0·48–0·96). In a cohort of metastatic ccRCC patients treated with immunotherapy, the inverse association with OS was no longer significant after adjustment for International Metastatic Database Consortium risk score (median OS 49.87, 95%CI 31.77-NR vs. 15.61, 95%CI 11.71–30.20, respectively; aHR 0·72, 95%CI 0·40–1·30). Tumors of obese patients were characterized by increased angiogenesis expression (false discovery rate-adjusted p-value=0·01) but showed no significant differences in immune cell programs. We found increased peritumoral adipose tissue inflammation (p<0.05) in obese versus normal weight patients. Interpretation Tumor microenvironmental differences in both the tumor and peritumoral adipose tissue by BMI may contribute to the apparent survival advantage experienced by obese ccRCC patients. The complex interplay between the ccRCC tumor and peritumoral adipose tissue microenvironment may have clinical relevance and warrants further investigation. Funding Ruth L. Kirschstein Research Service Award, ACSO YIA, Ludwig Center MSK, Weiss Family Kidney Research Fund, Novartis, The Sidney Kimmel Center for Prostate and Urologic Cancers and the NIH/NCI to MSKCC through the Cancer Center Support Grant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Cited by
Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., Salati, M., Dottorini, L., Iaculli, A., Varricchio, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3520 · Cited by 530
Obesity and the risk of cardiometabolic diseases
Valenzuela, P. L., Carrera-Bastos, P., Castillo-García, A., Lieberman, D. E., Santos-Lozano, A., & Lucia, A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00847-5 · Cited by 452
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Chowell, D., Yoo, S.-K., Valero, C., Pastore, A., Krishna, C., Lee, M., Hoen, D., Shi, H., Kelly, D. W., Patel, N., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01070-8 · Cited by 260
Self-citationSamnani, S., Sachedina, F., Gupta, M., Guo, E., & Navani, V. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.02 · Cited by 12
Gillessen, S., Gobat, K., Cathomas, R., Fischer, N., Pereira Mestre, R., Hermanns, T., Rothschild, S. I., Mach, N., Mingrone, W., Ciriolo, M., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.03.001 · Cited by 4
Metadata
- Authors
- Sanchez, A., Furberg, H., Kuo, F., Vuong, L., Ged, Y., Patil, S., Ostrovnaya, I., Petruzella, S., Reising, A., Patel, P., Mano, R., Coleman, J., Russo, P., Liu, C. H., Dannenberg, A. J., Chan, T. A., Motzer, R., Voss, M. H., & Hakimi, A. A.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 21
- Issue
- 2
- Pages
- 283-293
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2994822278
- Cited by
- 181
- References
- 16
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30797-1
- The paper
- Sanchez, A., Furberg, H., Kuo, F., Vuong, L., Ged, Y., Patil, S., Ostrovnaya, I., Petruzella, S., Reising, A., Patel, P., Mano, R., Coleman, J., Russo, P., Liu, C. H., Dannenberg, A. J., Chan, T. A., Motzer, R., Voss, M. H., & Hakimi, A. A. (2020). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30797-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.